Table V.
Univariate analyses of prognostic factors affecting overall survival of patients with non-bone-only metastasis.
| Overall survival, % | ||||
|---|---|---|---|---|
| Characteristic | N (%) | 3 years | 5 years | P-value |
| Age at diagnosis of metastasis, years | 0.008 | |||
| ≤35 | 85 (7.9) | 36.0 | 8.0 | |
| >35 | 997 (92.1) | 48.1 | 23.9 | |
| Lymph node status | 0.077 | |||
| Negative | 325 (30.0) | 50.7 | 26.4 | |
| Positive | 757 (70.0) | 45.5 | 21.7 | |
| Tumor stage | 0.007 | |||
| T1-2 | 844 (78.0) | 48.8 | 25.1 | |
| T3-4 | 238 (22.0) | 41.0 | 15.5 | |
| Clinical stage | 0.205 | |||
| I | 151 (14.0) | 49.4 | 26.1 | |
| II | 447 (41.3) | 49.6 | 25.7 | |
| III | 382 (35.3) | 44.1 | 19.2 | |
| IV | 102 (9.4) | 42.1 | 14.1 | |
| Pathologic type | 0.437 | |||
| Invasive ductal carcinoma | 909 (84.0) | 45.7 | 24.6 | |
| Others | 173 (16.0) | 54.3 | 18.6 | |
| HR status | <0.001 | |||
| Negative | 422 (39.0) | 36.4 | 15.4 | |
| Positive | 660 (61.0) | 54.3 | 28.6 | |
| HER2 status | 0.943 | |||
| Negative | 814 (75.2) | 47.5 | 23.2 | |
| Positive | 268 (24.8) | 46.2 | 23.6 | |
| Molecular subtype | <0.001 | |||
| HR+/HER2− | 538 (49.7) | 54.2 | 28.0 | |
| HR/HER2+ | 268 (24.8) | 46.2 | 23.6 | |
| HR−/HER2− | 276 (25.5) | 34.5 | 14.7 | |
HR, hormone receptor; HER2, human epidermal growth factor receptor 2.